{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Schiller HB"],"funding":["NHLBI NIH HHS"],"pagination":["1298-1310"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6913086"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["196(10)"],"pubmed_abstract":["<h4>Rationale</h4>Analyzing the molecular heterogeneity of different forms of organ fibrosis may reveal common and specific factors and thus identify potential future therapeutic targets.<h4>Objectives</h4>We sought to use proteome-wide profiling of human tissue fibrosis to (1) identify common and specific signatures across end-stage interstitial lung disease (ILD) cases, (2) characterize ILD subgroups in an unbiased fashion, and (3) identify common and specific features of lung and skin fibrosis.<h4>Methods</h4>We collected samples of ILD tissue (n = 45) and healthy donor control samples (n = 10), as well as fibrotic skin lesions from localized scleroderma and uninvolved skin (n = 6). Samples were profiled by quantitative label-free mass spectrometry, Western blotting, or confocal imaging"],"journal":["American journal of respiratory and critical care medicine"],"pubmed_title":["Deep Proteome Profiling Reveals Common Prevalence of MZB1-Positive Plasma B Cells in Human Lung and Skin Fibrosis."],"pmcid":["PMC6913086"],"funding_grant_id":["R01 HL097163","R33 HL120770"],"pubmed_authors":["Schwartz DA","Preisendorfer S","Moinzadeh P","Krieg T","Staab-Weijnitz C","Eckes B","Leuschner G","Mann M","Hatz RA","Behr J","Schiller HB","Mayr CH","Strunz M","Eickelberg O"],"additional_accession":[]},"is_claimable":false,"name":"Deep Proteome Profiling Reveals Common Prevalence of MZB1-Positive Plasma B Cells in Human Lung and Skin Fibrosis.","description":"<h4>Rationale</h4>Analyzing the molecular heterogeneity of different forms of organ fibrosis may reveal common and specific factors and thus identify potential future therapeutic targets.<h4>Objectives</h4>We sought to use proteome-wide profiling of human tissue fibrosis to (1) identify common and specific signatures across end-stage interstitial lung disease (ILD) cases, (2) characterize ILD subgroups in an unbiased fashion, and (3) identify common and specific features of lung and skin fibrosis.<h4>Methods</h4>We collected samples of ILD tissue (n = 45) and healthy donor control samples (n = 10), as well as fibrotic skin lesions from localized scleroderma and uninvolved skin (n = 6). Samples were profiled by quantitative label-free mass spectrometry, Western blotting, or confocal imaging","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Nov","modification":"2025-05-29T22:03:33.617Z","creation":"2025-05-29T22:03:33.617Z"},"accession":"S-EPMC6913086","cross_references":{"pubmed":["28654764"],"doi":["10.1164/rccm.201611-2263OC","10.1164/rccm.201611-2263oc"]}}